Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States.
P, G., J, J., L, H., S, B., L, L., J, B., M, B., E, F., S, S., & K, A. (2026). Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States.. Journal of medical economics. https://doi.org/10.1080/13696998.2026.2671565
P G, J J, L H, S B, L L, J B, et al. Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States.. Journal of medical economics. 2026; doi: 10.1080/13696998.2026.2671565
P G, J J, L H, et al. Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States.[J]. Journal of medical economics. 2026. DOI: 10.1080/13696998.2026.2671565.
@article{p2026,
author = {Gebrehiwet P and Jackson J and Hargreaves L and Barlow S and LeBrocq L and Brekke J and Butzner M and Freeman E and Shreay S and Akita K},
title = {Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States.},
journal = {Journal of medical economics},
year = {2026},
doi = {10.1080/13696998.2026.2671565},
note = {PMID: 42223221},
}
TY - JOUR AU - Gebrehiwet P AU - Jackson J AU - Hargreaves L AU - Barlow S AU - LeBrocq L AU - Brekke J AU - Butzner M AU - Freeman E AU - Shreay S AU - Akita K TI - Real-world burden of hypertrophic cardiomyopathy on healthcare use and health-related quality of life in Italy, Spain, and the United States. T2 - Journal of medical economics PY - 2026 DO - 10.1080/13696998.2026.2671565 AN - PMID:42223221 ER -
BACKGROUND AND AIMS: Hypertrophic cardiomyopathy (HCM) is a chronic, progressive, genetic heart disease characterized by hypercontractility and hypertrophy. As treatment options evolve, characterizing the existing healthcare needs and health-related quality of life (HRQoL) for patients with HCM is important. METHODS: Data were derived from the Adelphi Real World HCM Disease Specific Programme, a cross-sectional survey in Italy, Spain, and the United States. Physicians reported demographic and clinical characteristics; patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ-23), EQ-5D-5L and EQ-VAS, and the Work Productivity and Activity Impairment (WPAI) questionnaire. Outcomes were statistically compared by New York Heart Association (NYHA) class or KCCQ clinical summary score (KCCQ-CSS) to assess impact of disease severity. RESULTS: Patient mean age was 56.5 ± 14.8 years; 60.7% were male, and 78.3% had NYHA class II disease. Patients most commonly received beta blockers (88.4%) and diuretics (31.8%). HCM-related hospitalizations were reported for 25.8% of patients, increasing with higher NYHA or lower KCCQ-CSS. Mean EQ-5D-5L was 0.85, while EQ-VAS was 75.0, both decreasing with higher NYHA class or lower KCCQ-CSS. Overall work impairment and activity impairment (WPAI) were 16.1% and 26.6%, respectively, increasing with higher NYHA class or lower KCCQ-CSS. CONCLUSION: Our data show a significant remaining symptom burden and healthcare resource utilization (HCRU), as well as impact on HRQoL, work productivity, and daily activities, despite treatment intervention across a commonly applied measure of disease severity in HCM. These findings underscore the need for new treatments that can reduce HCRU and improve HRQoL of patients with HCM.